Otsuka is moving to buy Transcend Therapeutics for about $700 million upfront (roughly $1.2 billion total deal value), positioning the Japanese drugmaker to enter or expand psychiatric pipelines aimed at enhancing neuroplasticity. The transaction would be carried out through Otsuka’s American subsidiary and could include up to $525 million in additional milestones. Transcend’s lead program, TSND-201, is a methylone analog intended to rapidly and sustainably enhance neuroplasticity. In parallel with the deal, the company has pointed to a mid-stage PTSD dataset published in JAMA Psychiatry and is now running a Phase 3 trial in the US. The acquisition reflects broader pharma interest in psychiatric approaches that try to deliver faster functional rewiring—while avoiding some mechanistic issues associated with earlier MDMA-based efforts in PTSD.